W hen GlaxoSmithKline spins off its enormous division selling drugstore staples like Advil and Tums next month, it will represent more than just the latest shuffling of assets among corporate giants. ...
Tag: Sciences
Gilead Sciences Shares Cross 5% Yield Mark
In trading on Tuesday, shares of Gilead Sciences were yielding above the 5% mark based on its quarterly dividend (annualized to $2.92), with the stock changing hands as low as $57.16 on the day. Divid...
Turning Point Stock Doubles on Bristol Deal. What It Means for Biotech M&A.
Text size Photograph by Georges Gobet/AFP/Getty Images Turning Point Therapeutics stock has more than doubled after Bristol Myers Squibb announced that it had agreed to buy the company. It’s just the ...
Robots Pick Up More Work at Busy Factories
Robots are turning up on more factory floors and assembly lines as companies struggle to hire enough workers to fill rising orders. Orders for workplace robots in the U.S. increased by a record 40% du...
Big Pharma Has Enough Cash to Buy All of Biotech. Why M&A Isn’t Happening.
Text size Late last year, Barron’s predicted a wave of deals, citing biotech companies’ cash holdings. Above, the plates used to print one-dollar bills. Alex Wong/Getty Images With biotech...
Should I buy Gilead Sciences shares in May 2022?
Gilead Sciences, Inc. (NASDAQ: GILD) shares have weakened from $72.27 to $57.19 since the beginning of January 2022, and the current price stands around $59.39. Gilead Sciences reported better than ex...
Myovant Sciences provides an update on a supplemental new drug
Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) announced an update for an sNDA for MYFEMBREE, which is designed to manage severe to moderate pain linked to endometriosis. According to the ongoin...
The Arm deal is dead, but Nvidia is not expected to slow down
Nvidia Corp.’s acquisition of Arm Ltd. has been scuttled, but that isn’t expected to stop the chip maker’s charge into the data center. seeks to cut further into Intel Corp.’s and Advanced Micro Devic...
Here is where you can buy Cassava Sciences stock (SAVA): it is up 7% today
After dropping since mid-November, the price of Cassava Sciences stock (SAVA) has bounced back and today it is up 7.78%. The current bullish outlook is a result of a denial by the FDA against Citizen ...
Should I buy Gilead Sciences shares after strong Q4 results?
Gilead Sciences, Inc. (NASDAQ: GILD) shares remain under pressure even though the company reported strong fourth-quarter results last trading week. Gilead has increased quarterly dividend Gilead Scien...
8 tech stocks poised to bounce after Nasdaq plunge, according to AI platform
Nvidia Corp. tops a list of technology stocks that would be expected to bounce back strongly over the next month based on the reaction to past plunges by the Nasdaq Composite, according to an artifici...
‘The capitulation model for biotech is a Category 5 storm, the same as energy in 2020’ — why contrarians say the sector is a buy
If you want to know how much investors hate the biotech sector right now, consider this simple statistic: More than 25% of small biotech companies have stock-market capitalizations that are smaller th...